Bausch + Lomb (Abbreviated New Drug Application)
M&A
STATUS
M&A
LATEST DEAL TYPE
1
FINANCING ROUNDS
Description
Rights to an abbreviated new drug application (ANDA). The ANDA rights concern Nystatin Oral suspension, a treatment for candidiasis in the oral cavity.
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Pharmaceuticals
Acquirer
Hi-Tech Pharmaceuticals
Primary Office
- 1400 North Goodman Street
- Rochester, NY 14609
- United States
Bausch + Lomb (Abbreviated New Drug Application) Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore Bausch + Lomb (Abbreviated New Drug Application)‘s full profile, request access.
Request full access to PitchBookBausch + Lomb (Abbreviated New Drug Application) Former Investors
| Investor Name | Investor Type | Holding | Participating Rounds | Investor Since | Board Seat | Contact Info |
|---|
This information is reserved for PitchBook Platform users. To explore Bausch + Lomb (Abbreviated New Drug Application)‘s full profile, request access.
Request full access to PitchBook